Overview
Product name | Recombinant Human VEGFR-3/FLT-4 Protein |
---|
Catalog No. | RP00123 |
---|
Description | Recombinant Human VEGFR-3/FLT-4 Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Tyr25-Ile776) of human VEGFR3/FLT4 (Accession #NP_891555.2) fused with an Fc, 6×His tag at the C-terminus. |
---|
Bio-Activity | Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGF-C at 0.5 μg/mL (100 μL/well) can bind Recombinant Human VEGFR3 with a linear range of 3.92-15.70 ng/mL.
|
---|
Purity | > 95% by SDS-PAGE. |
---|
Endotoxin | < 0.1 EU/μg of the protein by LAL method. |
---|
Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation. |
---|
Species | Human |
---|
Calculated MW | 111.32 kDa |
---|
Background
The protein is a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA.
Product information
Synonym | FLT4; FLT-4; FLT41; LMPH1A; PCL; VEGFR-3; VEGFR3 |
---|
Expression Host | HEK293 cells |
---|
Tag | C-hFc&His |
---|
Swiss-Prot | |
---|
Gene ID | |
---|
Usage guide
Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
---|
Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
---|
* For research use only. Not for therapeutic or diagnostic purposes.